Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Person who had a heart attack within 1 - 3 years ago and at least one additional risk factor: Age ≥ 65 years old, Diabetes requiring medication, Documented history of 2nd prior MI (\>1 year ago). Angiographic evidence of multivessel CAD, and / or Chronic, non-end stage renal dysfunction.~* Females of child-bearing potential must have a negative pregnancy test at enrollment~* Persons who are currently taking aspirin between 75 and 150 mg once daily~Exclusion Criteria:~* Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start~* Persons who have planned coronary, cerebrovascular, or peripheral arterial Revascularization (invasive surgery) at study start~* Persons with known bleeding disorders~* Persons who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin~* Persons with a history of ischemic stroke~* Persons with a history of intracranial bleeding at any time, a tumor or blood vessel abnormality in the brain and/or spinal cord at any time, a history of surgery involving the brain or spinal cord within the last 5 years, or a history of bleeding from the gastrointestinal tract (eg, esophagus, stomach, colon, rectum) within the last 6 months or a major surgery within the last 30 days.~* Persons considered to be at risk of bradycardic events unless already treated with a permanent pacemaker~* Persons who have had open heart surgery within the past 5 years, unless the person had a heart attack after the surgery~* Persons with known severe liver disease~* Persons with kidney failure requiring dialysis~* Persons with life expectancy \< 1 year

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Oral Treatment
- 2 (Type: EXPERIMENTAL): Oral Treatment
- 3 (Type: PLACEBO_COMPARATOR): Oral Treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).